Vaccines against viral pathogens
AssigneeHexamer Therapeutics, Inc.
InventorsKeith Douglas Miller, Robert Bogden
Life of this patent
Estimating the term…
Loading patent…
AssigneeHexamer Therapeutics, Inc.
InventorsKeith Douglas Miller, Robert Bogden
Estimating the term…
The present disclosure describes a unique viral peptide (VP) vaccine for preventing or treating viral diseases. The vaccine is produced synthetically and includes no production steps in biological cells (e.g. E. coli, CHO cells, yeast cells) that would require subsequent endotoxin assays/removal or viral clearance procedures. The hC peptide is synthesized separately from the VP, and following self-assembly of the hC, the VP is covalently coupled to form the VP-hC conjugate which can serve as a vaccine for preventing or treating viral diseases. The hC includes heptad repeats following a specific pattern. Optionally, the VP-hC conjugate further includes one or more T-cell epitopes at the N- and/or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions comprising immunogenic compositions including VP-hC conjugate.
A viral peptide (VP) conjugate (VP-hC) or a VP oligomer (VPhC) comprising one or more viral peptides (VPs) covalently attached to a hapten carrier (hC), the hC comprising a monomeric peptide comprising SEQ ID NO:
A peptide immunogen comprising amino acid SEQ ID NO:
A peptide scaffold comprising amino acid SEQ ID NO:
Dependencies are inferred from the claim text.